Colorectal cancer (CRC) represents approximately 10% of all cancers and is the second
most common cause of cancer deaths. Initial clinical presentation as metastatic CRC …

The incidence of hepatocellular carcinoma (HCC) has been rising worldwide over the last
20 years and is expected to increase until 2030 in some countries including the United …

Full integration of oncology and palliative care relies on the specific knowledge and skills of
two modes of care: the tumour-directed approach, the main focus of which is on treating the …

Colorectal cancer (CRC) is one of the most common malignancies in Western countries.
Over the last 20 years, and the last decade in particular, the clinical outcome for patients with …

Background Angiogenesis plays a role in the biology of ovarian cancer. We examined the
effect of bevacizumab, the vascular endothelial growth factor inhibitor, on survival in women …

The incidence of rectal cancer in the European Union is $125 000 per year, ie $35% of the
total colorectal cancer incidence, reflecting 15–25 cases/100000 population per year and is …

Background Intravenous bolus fluorouracil plus leucovorin is the standard adjuvant
treatment for colon cancer. The oral fluoropyrimidine capecitabine is an established …

Background The ICON7 trial previously reported improved progression-free survival in
women with ovarian cancer with the addition of bevacizumab to standard chemotherapy …

Purpose Panitumumab is a fully human anti–epidermal growth factor receptor (EGFR)
monoclonal antibody that improves progression-free survival (PFS) in chemotherapy …

Purpose In metastatic colorectal cancer, a combination of leucovorin (LV) and fluorouracil
(FU) with oxaliplatin (FOLFOX) 4 is a standard first-line regimen. The cumulative …